Clinical Trials Logo

Filter by:
NCT ID: NCT05974007 Recruiting - Clinical trials for Non-Small Cell Lung Cancer

Neoadjuvant Treatment Real-world Clinical Outcomes in NSCLC

NeoR-World
Start date: January 1, 2022
Phase:
Study type: Observational

Despite the clinical success of immune checkpoint blockade (ICB), in neoadjuvant setting, there is still a lack of valid data for operable NSCLC in the real world. This study aim to compare the clinical outcomes (pathologic response rate versus survival) of neoadjuvant immunochemotherapy with neoadjuvant chemotherapy in the real world, to explore the impact of clinicopathological factors on clinical outcomes in neoadjuvant immunochemotherapy setting, and to identify potential neoadjuvant immunochemotherapy beneficiaries.

NCT ID: NCT05973721 Recruiting - Pib Specific Phage Clinical Trials

Clinical Study of Phage Therapy for Chronic Constipation Efficacy and Safety

Start date: July 1, 2023
Phase: N/A
Study type: Interventional

The overall aim was to evaluate the efficacy of PiB-specific phages for the treatment of refractory constipation through clinical studies, primarily for the publication of scientific papers and to guide the development of phage therapies. The purpose of this study will be subdivided into three aspects from three aspects: target exposure level, target occupation, and functional effects after acting on the target, including:1) The distribution of PIB phage in the intestine of patients with refractory constipation;2) The killing effect of PIB phage on PIB bacteria in refractory constipation patients;And 3) therapeutic effect of PIB phage on patients with refractory constipation.

NCT ID: NCT05973149 Not yet recruiting - Prostate Cancer Clinical Trials

Trial of QLH12016 in Patients With Metastatic Castration Resistant Prostate Cancer

Start date: August 31, 2023
Phase: Phase 1
Study type: Interventional

To evaluate the tolerance, safety, pharmacokinetics, and preliminary anti-tumor activity of QLH12016 in patients with metastatic castration resistant prostate cancer

NCT ID: NCT05973097 Recruiting - Oral Lichen Planus Clinical Trials

Treatment of Oral Lichen Planus With Paeoniflorin and Photodynamic Therapy

Start date: July 30, 2023
Phase: N/A
Study type: Interventional

Oral lichen planus (OLP) is a common chronic inflammatory disease of the oral mucosa and is considered a precancerous condition. It is characterized by white reticular changes in the oral mucosa, which can progress to erosions and cause pain in severe cases. The pathogenesis of OLP is still unclear, but it is believed to be a T-lymphocyte-mediated autoimmune disease. Currently, only symptomatic treatments are available, and there is no definitive cure. In this project, we plan to use TCM differentiation to categorize OLP patients and conduct a randomized controlled clinical trial to demonstrate the enhanced therapeutic effect of paeoniflorin combined with photodynamic therapy for OLP. The implementation of this project will provide new insights into the clinical management of OLP, improve our understanding of the treatment mechanisms, and have important theoretical and clinical implications.

NCT ID: NCT05973032 Completed - Clinical trials for Acute Lymphoblastic Leukemia, Pediatric

MRD Detection by NGS in Pediatric B-ALL

Start date: November 1, 2018
Phase:
Study type: Observational

This retrospective analysis aims to investigate pediatric patients with B-cell acute lymphoblastic leukemia who were detected for minimal residual disease (MRD) using next-generation sequencing (NGS). The study will utilize second-generation sequencing technology to analyze the rearrangement of the immunoglobulin heavy chain (IGH), immunoglobulin kappa light chain (IGK), and immunoglobulin lambda light chain (IGL) genes in these patients. Patients will be stratified based on NGS-MRD levels, and the relationship between NGS-MRD and Event-Free Survival (EFS) will be evaluated.

NCT ID: NCT05972655 Recruiting - Low Rectal Cancer Clinical Trials

Nodes-sparing Short-course Radiation Combined With CAPOX and Tislelizumab for MSS Middle and Low Rectal Cancer

mRCAT
Start date: August 2, 2023
Phase: Phase 2
Study type: Interventional

This is an open-label, prospective, multicenter phase II clinical trial to evaluate modified short-course radiation (Radiation targeting the tumor bed without irradiating surrounding tumor-draining lymph nodes) combined with CAPOX and PD-1 Inhibitor (Tislelizumab) for patients with MSS middle and low rectal cancer. A total of 32 patients will be enrolled in this trial. The primary endpoint is the rate of pathological complete response (pCR). The organ preservation rate, tumor regression grade, long-term prognosis, and adverse effects will also be analyzed.

NCT ID: NCT05972473 Recruiting - Clinical trials for Neovascular Age-related Macular Degeneration

A Study to Evaluate the Efficacy and Safety of IBI302 in Subjects With nAMD

Start date: August 15, 2023
Phase: Phase 3
Study type: Interventional

The study is designed for multi-center,randomized,double-masked,active-contralled study to evaluate effective and security of intravitreal injection of IBI302 in subjects with neovascular age-related macular degeneration.

NCT ID: NCT05972460 Recruiting - Clinical trials for Advanced Solid Tumors

IMM2510, a PD-L1 and VEGF Bispecific Fusion Protein, in Patients With Advanced Solid Tumors

Start date: August 18, 2021
Phase: Phase 1
Study type: Interventional

This trial is a first-in-human, open-label, multi-center, dose escalation phase 1a study followed by cohort expansion phase 1b study to evaluate the safety, efficacy, pharmacokinetics (PK) and pharmacodynamics (PD) of IMM2510, a PD-L1 and VEGF bispecific fusion protein, in patients with advanced solid tumors.

NCT ID: NCT05972252 Recruiting - Clinical trials for Acute Ischemic Stroke

First-in-man Study of the Cerebrovascular Interventional Procedural Control System

Start date: October 15, 2023
Phase: N/A
Study type: Interventional

The objective of this study the first human use of a new device in treatment of acute ischemic stroke, which to evaluate the feasibility, safety, and efficacy of the Cerebrovascular Interventional Procedural Control System.

NCT ID: NCT05972057 Recruiting - Delirium Clinical Trials

Prediction Model of Long-term Cognitive Dysfunction and Delirium After Cardiac Surgery

Start date: August 1, 2023
Phase:
Study type: Observational

Delirium is a clinical syndrome caused by normal dysfunction of the brain, characterized by reduced awareness and responsiveness to the environment, as well as orientation disorders, incoherent thinking and memory disorders. Delirium indicates poor recovery of cognitive function, decreased ability of daily life, may need to enter nursing homes, and even lead to adverse outcomes such as death. According to a number of clinical studies, middle-aged and elderly people are prone to delirium after undergoing major surgery. Delirium occurs in 31 % -40 % of patients over 50 years old after cardiac surgery. Compared with patients without postoperative delirium, patients with postoperative delirium had significant cognitive impairment within 1 year after cardiac surgery. The occurrence of delirium suggests that the patient 's brain has become fragile, cognitive function has begun to decline, and the risk of future dementia has increased. Secondly, delirium and dementia have overlapping clinical features and common pathogenic mechanisms. Some scholars even speculate that delirium and dementia represent different stages of a common process. It is generally believed that the peripheral immune system may be involved in the pathogenesis and progression of dementia through the dysfunctional blood-brain barrier. The activation of microglia and astrocytes leads to the release of chemokines, which can recruit peripheral immune cells to the central nervous system. At the same time, cytokines released by peripheral cells can cross the blood-brain barrier and act on glial cells to change their phenotype. This study is a prospective cohort study of patients aged 65 and over who are about to undergo elective cardiac surgery.CyTOF can achieve accurate immunophenotyping of cell populations while comprehensively and accurately detecting and analyzing cytokines and signaling pathways. Therefore, the detection of peripheral blood biomarkers may effectively predict the risk of long-term cognitive dysfunction and postoperative delirium in patients undergoing cardiac surgery.